Biotech Values

[DewDiligence]

MGNX—I think this is your answer:

https://www.fool.com/earnings/call-transcripts/2020/05/06/macrogenics-inc-mgnx-q1-2020-earnings-call-transcr.aspx

I would like to turn to the clinical abstracts that have been selected for presentation at the upcoming ASCO Annual Meeting that will be held virtually at the end of May.

The first is an oral presentation covering dose escalation and select expansion cohorts from the ongoing Phase 1 study of MGD013, our investigational bispecific PD-1xLAG-3 DART molecule. The overall safety profile of MGD013 as it relates to immune-mediated toxicity is generally consistent with anti-PD-1 molecules with respect to event type and frequency. We have not identified the maximum tolerated dose. Tumor-specific expansion cohorts have been treated at a flat dose of 600 milligrams once every two weeks. Among the evaluable patients we are observing activity of MGD013 across expansion cohorts in several tumor types, including after anti-PD-1 therapy, which warrants further investigation.

…Most notably, and as you will hear more about at ASCO, in a cohort of over a dozen valuable patients with advanced HER2-positive tumors treated with a combination of MGD013 and margetuximab, we observe confirmed and unconfirmed objective responses in excess of 40%. All responders remain on therapy. We are very encouraged by this observation that we believe represents synergistic activity of the two molecules based on our results in monotherapy studies.